Clinical Trial: Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency

Brief Summary: This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: Area Under the Curve (AUC(0 to infinity)) of anacetrapib [ Time Frame: through 168 hours post dose ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Tolerability of a single dose administration of 100mg anacetrapib, measured by the number of clinical and laboratory adverse events [ Time Frame: through 14 days post dose ]

Original Secondary Outcome: Same as current

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: April 29, 2010
Date Started: May 2010
Date Completion:
Last Updated: October 12, 2015
Last Verified: October 2015